HEPATITIS C BASICS ILAN S. WEISBERG, MD DIRECTOR HEPATOLOGY LENOX HILL HOSPITAL JUNE 20, 2015
|
|
- Sharlene Hood
- 6 years ago
- Views:
Transcription
1 HEPATITIS C BASICS ILAN S. WEISBERG, MD DIRECTOR HEPATOLOGY LENOX HILL HOSPITAL JUNE 20, 2015
2 Overview Understand the GLOBAL and US burden of chronic HCV infec<on Review the natural history of HCV infec<on Realize current HCV screening guidelines Recognize the impact that disease eradica<on has on the natural history of HCV related complica<ons
3 GLOBAL PREVALENCE OF HCV >2.9% 2.0%- 2.9% 1.0%- 1.9% <1.0% No data available Perz JF, et al. 42nd Annual Mee<ng of IDSA; Boston, MA; Sept 30- Oct 3, Data source: World Health Organiza<on.
4 Hepa<<s C Genome Heterogeneity 7 distinct genotypes 30% difference at nucleotide level 25% - 30% difference at amino acid level Long-standing viral diversity Simmonds P. Curr Stud Hematol Blood Transfus. 1998;62:49-50.
5 USA Genotype Distribu<on Genotypes 4,5,6 3% Genotypes 2 and 3 22% Genotype 1 75% Hoofnagle JH. Hepatology 2002;36:S21- S29. McHutchison JG, et al. N Engl J Med 2009;361:
6 USA: BURDEN OF DISEASE 180 million people infected worldwide 4-5 million (2%) in the USA Primary indica<on for liver transplant Leading cause of liver related death 7 to 13 thousand deaths annually Extrahepa<c manifesta<ons less well recognized: NHL, MCL 4-5 million 75% Institute of Medicine. Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C; 2010."
7 HCV Is Leading Cause of Liver Transplants in the US Primary cause of disease among adults on the liver transplant wait list, 2011 Primary cause of disease among adult liver transplant recipients, 2011 Acute hepatic necrosis HBV Malignancy 2.6% 2.8% All others 26.4% 6.0% Cholestatic disease 9.0% HCV 30.1% Alcoholic liver disease 23.2% Metabolic liver disease Acute hepatic necrosis Cholestatic disease 2.5% 4.0% All others 22.3% 9.1% Alcoholic liver disease 17.6% HCV 23.5% Malignancy 20.9% Available at: hcp://srtr.transplant.hrsa.gov/annual_reports/2011/pdf/03_%20liver_12.pdf.
8 CumulaRve Mortality (%) HCV Viremia Was Associated With Increased Mortality in a Prospec<ve Taiwanese Cohort Study AnR- HCV+, HCV RNA detectable AnR- HCV+, HCV RNA undetectable AnR- HCV All Causes (n=2394) %* % 12.4% Liver Cancer (n=115) 10.4%* 1.6% 0.3% ExtrahepaRc Diseases (n=2199) 19.8%* 12.2% 11.0% Follow- Up (Years) Follow- Up (Years) Follow- Up (Years) REVEAL HCV: Risk Evalua<on of Viral Load Eleva<on and Associated Liver Disease/Cancer ( ). An<- HCV seronega<ve (n=18,541); an<- HCV seroposi<ve (n=1095; detectable HCV RNA: 69.4%). Average follow- up: 16.2 years. Among extrahepa<c causes of death, 68.5% and 69.3% were noncancer deaths for HCV seronega<ve and seroposi<ve, respec<vely. *P<.001 for comparison among all 3 groups and P<.001 for HCV RNA detectable vs undetectable. Lee M- H, et al. J Infect Dis. 2012;206:
9 Higher Cancer Rates in HCV Patients: Real-World Evidence from a Large Health Maintenance Organization Cancer diagnosis rate is higher for HCV pa<ents vs. non- HCV pa<ents, even when excluding liver cancer (p<0.001) Univariate analysis shows that cancer rates were significantly higher for liver cancer, non- Hodgkin lymphomas, and total cancer sites Cancer rates are higher in HCV parents; these results suggest another possible manifestaron of HCV ALL SITES (W/O HCC) ALL SITES (W/ HCC) PROSTATE RENAL LUNG HEAD / NECK NON-HODGKIN LYMPHOMA CRUDE HCV vs. NON- HCV CANCER RATES MYELOMA PANCREAS LIVER COLON / RECTUM STOMACH ESOPHAGUS * * * * * * * * * * * * ** RATE RATIO (95% CI): HCV vs. NON-HCV *p<0.001; **p<0.005 Nyberg AH, EASL, 2015, O058
10 NATURAL HISTORY OF HCV INFECTION Acute Infec<on Chronic HCV Asymptoma<c Infec<on years Cirrhosis HCC ESLD
11 GROWING BURDEN OF HCV MORBIDITY AND MORTALITY Na<onal mul<ple cause mortality data from HCV related deaths have overtaken HIV HCV related deaths increased to >15,000 73% of deaths occurred in persons age Mortality Rate per 100,000 Persons Ly KN et al Annals of Internal Medicine
12 FORECASTING THE MORBIDITY AND MORTALITY OF HCV IN THE USA Rein et al. Journal of Diges<ve and Liver Disease. 2010
13 HCV Disease Burden in the U.S. q 1.76 million will develop cirrhosis q 418,000 will develop liver cancer, and q 1,071,000 will die from complications of hepatitis C infection or 1/3 of all persons currently infected Rein, DB, Wittenborn, JS, Weinbaum, CM, et al. Journal of Digestive Liver Diseases 2010.
14 Increasing Health Care Costs Associated With Progressive Liver Disease in the Aging HCV- Infected Popula<on Prevalence (95% CI) Health Care Cost (95% CI) While the prevalence of HCV infec<on is declining from its peak, the incidence of advanced liver disease and associated health care costs con<nue to rise Modeling does not take into account any impact of birth cohort screening A system dynamic modeling framework was used to quantify the HCV-infected population, the disease progression, and the associated cost from CI=confidence interval. Razavi H, et al. Hepatology Epub ahead of print.
15 Predictions for ,000 HCV deaths 720,700 million years of advanced liver disease 1.83 million years of life lost $11 billion in direct medical care costs $21.3 and $54 billion societal costs from premature disability and mortality Wong Am J Pub Health 2000
16 HCV- Infected Persons in the US: Es<mated Rates of Detec<on, Referral to Care and Cure CDC & USPSTF recommend 1-time testing of baby boomers (born ) X1000 persons % 32-38% 20-23% 7-11% 5-6% 0 Infected Diagnosed Referred HCV RNA Treated Cure to care test Holmberg S, N Engl J Med 2013; 368: 1859
17 RISK BASED SCREENING FOR HCV The op<mal approach to detec<ng HCV infec<on is to screen persons for a history of risk of exposure and test selected individuals who have an iden<fiable risk factor AASLD 2009 Injec<on drug use Blood Transfusion Prior to 1992 Hemophiliacs receiving blood products before 1987 Unexplained eleva<on in ALT Hemodialysis HIV Children of HCV Mothers Sexual Partners of HCV
18 CDC Has Revised Screening Recommenda<ons for HCV
19 New York State Law Goes into Effect January 1, 2014 HepaRRs C Virus TesRng (Chapter 425 of the Laws of 2013) This new law requires a hepa<<s C virus screening test to be offered to all pa<ents born between 1945 and 1965 who are receiving health services as a hospital inpa<ent or receiving primary care services and applies to physician, physician assistant, or nurse prac<<oner. The law further requires that the health care provider refer a pa<ent who receives a posi<ve screening test to another provider to receive confirmatory tes<ng and follow- up care.
20 Rising incidence of HCV in non- urban individuals < 30 years of age MMWR May 2015 surveillance data % increase in acute HCV in persons < 25 from 4 Appalachian states (KY, TN, WV, VA) Primarily non- hispanic white individuals from non- urban communi<es Associated with increased injec<on of prescrip<on opioid analgesics Similar findings reported in analagous popula<ons in Upstate NY Zibbel et al. MMWR May 2015 Aibbel et al. Am J Pub Health. 2014
21 EVOLUTION OF HCV THERAPY 2015 > 95% SVR RATE (%) % % % % 2011 ~70%
22 IMPACT OF SVR ON NATURAL HISTORY OF HCV INFECTION NonResponders SVR Decompensa<on 13% 1.3% Liver Transplanta<on 11% 0.7% Hepatocellular Carcinoma 9.1% 1.4% Liver Related Death 6.8% 0.7% Everson et al. HALT- C Study Group Lok et al. HALT- C Study Group
23 SVR Associated with a Reduc<on in All- Cause Mortality SVR Backus L, Boothroyd D, Phillips B, et al. Clin Gastro Hepatol 2011.
24 Conclusions Global and US burden of HCV is rising as the infected popula<on ages Tremendous toll an<cipated for both individuals living with HCV and health care delivery systems To change the disease, efforts to improve screening must be coupled with increased access to highly ac<ve an<viral medica<ons
25 Thank You. Happy Father s Day.
HCV Viremia Was Associated With Increased Mortality in a Prospective Taiwanese Cohort Study
Tram T. Tran, MD, FACG Approach to HCV Treatment in Patients with HCC Tram T. Tran, MD, FACG Professor of Medicine Medical Director, Liver Transplant Cedars Sinai Medical Center Natural History of HCV
More informationAri Bunim, M.D. Director of Hepatology New York Hospital Queens Assistant Professor of Clinical Medicine Weill Cornell Medical College
Ari Bunim, M.D. Director of Hepatology New York Hospital Queens Assistant Professor of Clinical Medicine Weill Cornell Medical College New York State Law Goes into Effect January 1, 2014 Hepatitis C Virus
More informationViral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital
Viral Hepatitis Dr Melissa Haines Gastroenterologist Waikato Hospital Viral Hepatitis HAV HBV HCV HDV HEV Other viral: CMV, EBV, HSV Unknown Hepatitis A Hepatitis A Transmitted via the faecal-oral route
More informationHepatitis C. Core slides
Hepatitis C Core slides This material was prepared by the Viral Hepatitis Prevention Board The slides (or subsets) can be reproduced for educational use only, with reference to the original source and
More informationNothing to disclose. Screening for and treatment of Hepa11s B and C 2/18/15
Screening for and treatment of Hepa11s B and C Lisa Winston, MD University of California, San Francisco San Francisco General Hospital Nothing to disclose. 1 Hepa11s B Epidemiology Pathogenesis Lecture
More informationStrategies to Address HCV
Strategies to Address HCV HIV Programs & U.S. Viral Hepatitis Action Plan Corinna Dan, RN, M.P.H. Viral Hepatitis Policy Advisor Office of HIV/AIDS and Infectious Disease Policy September 10, 2015 1 The
More informationWorldwide Causes of HCC
Approach to HCV Treatment in Patients with HCC JORGE L. HERRERA, MD, MACG UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE Worldwide Causes of HCC 60% 50% 40% 54% 30% 20% 10% 31% 15% 0% Hepatitis B Hepatitis
More informationThe impact of the treatment of HCV in developing Hepatocellular Carcinoma
The impact of the treatment of HCV in developing Hepatocellular Carcinoma Paul Y Kwo, MD Professor of Medicine Medical Director, Liver Transplantation Gastroenterology/Hepatology Division Indiana University
More informationImproving Access & Linkage to Care in Underserved Populations & Baby Boomers
Improving Access & Linkage to Care in Underserved Populations & Baby Boomers Lesley Miller MD Medical Director, Grady Liver Clinic Associate Professor of Medicine Division of General Medicine and Geriatrics
More informationSTOP Hepatocellular Carcinoma
STOP Hepatocellular Carcinoma Laura Tenner MD MPH, Amit G. Singal MD MS, Mamta Jain MD, Barbara Turner MD, Barbara Riske MS ReACH Center and Dept of Medicine UT Health San Antonio Dept of Medicine UT Southwestern
More informationHepatitis C Screening For Baby Boomers in Primary Care. Nicole Mesick DO, RD NHAFP Conference May 18 th, 2018
Hepatitis C Screening For Baby Boomers in Primary Care Nicole Mesick DO, RD NHAFP Conference May 18 th, 2018 Disclosures No disclosures Objectives Recognize the importance of diagnosing Hepatitis C (HCV)
More informationHEPATITIS C TREATMENT UPDATE
HEPATITIS C TREATMENT UPDATE Hepatitis C: Burden of Disease in USA HCV is generally asymptomatic until advanced liver disease 4.1 million persons ever infected; 3.2 million chronic infections Up to 75%
More informationViral hepatitis and Hepatocellular Carcinoma
Viral hepatitis and Hepatocellular Carcinoma Hashem B. El-Serag, MD, MPH Dan L. Duncan Professor of Medicine Chief, Gastroenterology and Hepatology Houston VA & Baylor College of Medicine Houston, TX Outline
More informationEpidemiology and Screening for Hepatitis C Infection
Epidemiology and Screening for Hepatitis C Infection Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Epidemiology/Screening for Hepatitis
More informationRecommendations for Hepatitis C Screening
Hepatitis C Online PDF created June 16, 2018, 9:14 am Recommendations for Hepatitis C Screening This is a PDF version of the following document: Module 1: Screening and Diagnosis of Hepatitis C Infection
More informationHCV in the Latino Community -Epidemiology, Natural History, Risk Factors, Screening and Diagnosis
HCV in the Latino Community -Epidemiology, Natural History, Risk Factors, Screening and Diagnosis Wari Allison MD, PhD Assistant Professor/Research Dept. of Medicine/Infectious Disease Medical Director
More informationWorldwide Causes of HCC
Approach to HCV Treatment in Patients with HCC Mark W. Russo, MD, MPH, FACG Carolinas HealthCare System Charlotte Worldwide Causes of HCC 60% 50% 40% 30% 20% 10% 0% 54% 31% 15% Hepatitis B Hepatitis C
More informationSECTION 1: ABOUT HEPATITIS
SECTION 1: ABOUT HEPATITIS Hepa33s means swollen liver Many things can cause your liver to become swollen, including drinking a lot of alcohol; taking certain medica3ons or herbs; inhaling toxic fumes;
More informationNIH Consensus Conference Statement. Management of Hepatitis C. March 24-26, NIH Web site. Available at:
ABC s of Hepatitis C Treatment Today Elizabeth N. Britton, MSN, FNP-BC Hepatology Services Louisiana State University Health Sciences Center ebritt@lsuhsc.edu ANAC CONFERENCE -TUCSON NOV 2012 Hepatitis
More informationSECTION 1: ABOUT HEPATITIS
SECTION 1: ABOUT HEPATITIS Hepa33s Means Swollen Liver Many things can cause your liver to become swollen, including drinking a lot of alcohol; taking certain medica3ons or herbs; inhaling toxic fumes;
More informationOvercoming Barriers to HCV Care
Overcoming Barriers to HCV Care STACEY B. TROOSKIN MD PHD DIRECTOR OF VIRAL HEPATITIS PROGRAMS PHILADELPHIA FIGHT COMMUNITY HEALTH CENTERS PHILADELPHIA, PA Disclosures Grant Support from Gilead Sciences,
More informationHepatitis C. No disclosures. 1. The USPSTF recommends Hepatitis C screening in which patient populations?
Hepatitis C Jennifer Acosta PA-C No disclosures 1. The USPSTF recommends Hepatitis C screening in which patient populations? a. All adults at least once b. Immigrants to the US and those over age 65 c.
More informationHEPATITIS C VIRUS (HCV) GENOTYPE TESTING
CLINICAL GUIDELINES For use with the UnitedHealthcare Laboratory Benefit Management Program, administered by BeaconLBS HEPATITIS C VIRUS (HCV) GENOTYPE TESTING Policy Number: PDS - 027 Effective Date:
More informationZobair M. Younossi M.D., M.P.H., FACG
HCV Epidemiology and Cohort Screening Guidelines Zobair M. Younossi, MD, MPH, FACG Consultant or Advisor: Conatus, Enterome, Gilead, Merck, Salix, Vertex, J & J HCV Epidemiology and Cohort Screening Guidelines
More informationNational Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Increased Hepatitis C Virus (HCV) Detection in Women of Childbearing Age and Potential Risk for Vertical Transmission - United States
More informationHCV: Racial Disparities. Charles D. Howell, M.D., A.G.A.F Professor of Medicine University of Maryland School of Medicine Baltimore, MD
HCV: Racial Disparities Charles D. Howell, M.D., A.G.A.F Professor of Medicine University of Maryland School of Medicine Baltimore, MD Charles Howell Disclosures Research Grants Boehringer Ingelheim, Inc.
More informationTREATING HEPATITIS C TODAY
TREATING HEPATITIS C TODAY Nikolaos K. Gatselis Department of Medicine& Research Laboratory of Internal Medicine, Larissa Medical School, Thessaly University Disclosure Research Support: Gilead, Janssen,
More informationHepatitis C in the United States : Preparing for the Test and Cure Era
Hepatitis C in the United States : Preparing for the Test and Cure Era Division of Viral Hepatitis National Center for HIV/AIDS, Viral Hepatitis, STD & TB Prevention Centers for Disease Control and Prevention
More informationQuelle est la contribu/on des troubles liés à l alcool au fardeau de l hépa/te C?
Quelle est la contribu/on des troubles liés à l alcool au fardeau de l hépa/te C? Vincent Mallet Université Paris Descartes, AP HP, Inserm, Paris, France vincent.mallet@aphp.fr Conflits d intérêts Vincent
More informationHCV TREATMENT OPTIONS
HCV TREATMENT OPTIONS Trea2ng HCV is never an emergency, but early treatment prevents further liver damage. DAAs are easier to take, and be0er tolerated than PEG- IFN and RBV. Treatment is recommended
More informationUpdate on Hepatitis B and Hepatitis C
Update on Hepatitis B and Hepatitis C Catherine Stedman Department of Gastroenterology, Christchurch Hospital and University of Otago, Christchurch Disclosures I have the following financial relationships
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hepatitis_c 1/1/2019 N/A 1/1/2020 1/1/2019 Description of Procedure or Service Description Hepatitis C is
More informationDigestive & Liver Disease Wellness
Digestive & Liver Disease Wellness Colorectal Cancer Screening & Prevention According to the American Cancer Society, this year 136,830 people in the U.S. According will be to diagnosed the American with
More informationi Screening and Natural History
HCV Epidemiology, i Screening and Natural History BRUCE A. LUXON, MD, PHD, FACG ANTON AND MARGARET FUISZ CHAIR IN MEDICINE PROFESSOR AND CHAIRMAN DEPARTMENT OF MEDICINE GEORGETOWN UNIVERSITY Hepatitis
More information26/09/2014. Types of Viral Hepatitis. Prevention of Viral Hepatitis as a Health Disparity for American Indians: Successes and Challenges
Rate per, Types of Viral Hepatitis A E B D C Prevention of Viral Hepatitis as a Health Disparity for American Indians: Successes and Challenges Source of virus Feces Feces Blood/bloodderived body fluids
More informationHCV Infection in the United States
New York State Department of Health HCV Infection in the United States ~4 million in the U.S. infected with chronic hepatitis C virus (HCV) 17,000 new infections per year 75 percent of adults with hepatitis
More informationManagement of Chronic HCV 2017 and Beyond
Management of Chronic HCV 2017 and Beyond Blaire E Burman, MD Virginia Mason Gastroenterology & Hepatology Relevant Disclosures No financial disclosures to report Leaning Objectives Burden of HCV Prevalence
More informationThe Dawn of a New Era: Hepatitis C
The Dawn of a New Era: Hepatitis C Naudia L. Jonassaint Assistant Professor of Medicine and Surgery University Pittsburgh School of Medicine December 1, 2015 Objectives After presentation the learner should
More informationUpdate on HIV-HCV Epidemiology and Natural History
Update on HIV-HCV Epidemiology and Natural History Jennifer Price, MD Assistant Clinical Professor of Medicine University of California, San Francisco Learning Objectives Upon completion of this presentation,
More informationHCV epi overview. Brigg Reilley, NPAIHB, Nat l Program Epidemiologist,
HCV epi overview Brigg Reilley, NPAIHB, Nat l Program Epidemiologist, brigg.reilley@ihs.gov In 20 minutes, we will cover Transmission/trends Screening HCV estimates: national, IHS, OK (federal), Cherokee
More informationHepatitis C Elimination: Screening, Linkage and Treatment. Eric Lawitz, MD The Texas Liver Institute San Antonio, Texas
Hepatitis C Elimination: Screening, Linkage and Treatment Eric Lawitz, MD The Texas Liver Institute San Antonio, Texas Hepatitis C: Worldwide Presence Worldwide prevalence: 130-150 million Viral hepatitis
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #400 (NQF 3059): One-Time Screening for Hepatitis C Virus (HCV) for Patients at Risk National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS F INDIVIDUAL MEASURES: REGISTRY ONLY
More informationAASLD, Boston, USA, 10 th November 2014 [oral presentation]
Effects of Sustained Virological Response on the of liver transplant, hepatocellular carcinoma, death and re-infection: meta-analysis of 129 studies in 34,563 patients with Hepatitis C infection. Andrew
More informationHepatitis C Knowledge Network Webinar Series
Hepatitis C Knowledge Network Webinar Series HCV Epidemiology: The Silent Epidemic Presented by: Michael Saag, MD, FIDSA IDSA Hepatitis Task Force Director, Center for AIDS Research University of Alabama
More informationHepatitis B: A Preventable Cause of Liver Cancer. Saira Khaderi MD, MPH Assistant Professor of Surgery Associate Director, Project ECHO June 17, 2016
Hepatitis B: A Preventable Cause of Liver Cancer Saira Khaderi MD, MPH Assistant Professor of Surgery Associate Director, Project ECHO June 17, 2016 Overview Epidemiology HBV and cancer Screening, Diagnosis
More informationPrimary Care Approach to Diagnosis and Management of Chronic Hepatitis C Brian Viviano, D.O.
Primary Care Approach to Diagnosis and Management of Chronic Hepatitis C Brian Viviano, D.O. Objectives Epidemiology of chronic hepatitis C CDC guidelines on screening or hepatitis C Diagnosing hepatitis
More informationPrevent Hepatocellular Carcinoma through Screening, Vaccination, and Treatment of Viral Hepatitis Milena Gould Suarez, MD
Prevent Hepatocellular Carcinoma through Screening, Vaccination, and Treatment of Viral Hepatitis Milena Gould Suarez, MD Hello, my name is Milena Gould Suarez, and today I will present "Prevent Hepatocellular
More informationHepatitis B. ECHO November 29, Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University
Hepatitis B ECHO November 29, 2017 Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University Disclosures Advisory board Gilead Comments The speaker Joseph
More informationHepatocellular carcinoma
Hepatocellular carcinoma Mary Ann Y. Huang, M.D., M.S., FAASLD Transplant hepatologist Peak Gastroenterology Associates Porter Adventist Hospital Denver, Colorado Background - Worldwide Hepatocellular
More informationGeo-epidemiology of Hepatitis C in Northeast Indiana
Geo-epidemiology of Hepatitis C in Northeast Indiana Shori Gerardot, Ashley Cross, Atit Patel, Kassidy Beck MS, Scott M. Stienecker MD, and Teresa A. Beam PhD Hepatitis C (HCV) ~180 million worldwide ~2.7-3.9
More informationNumbers HCV and HIV Epidemiology in the US
By The Numbers HCV and HIV Epidemiology in the US Coinfection Fridays Session 1 18 January 2019 Christopher B. Hurt, MD Associate Professor of Medicine Co-Director, North Carolina AIDS Training & Education
More informationHepa%%s C Epidemiology in West Virginia. Judith Feinberg, MD Project ECHO Nov. 3, 2016
Hepa%%s C Epidemiology in West Virginia Judith Feinberg, MD Project ECHO Nov. 3, 2016 Acute HCV in Appalachian Youth < 30 364% increase in cases (n=1377) from 2006-12 in WV, VA, TN & KY Similar to data
More informationHEPATITIS C : RECENT ADVANCES IN SCREENING & MANAGEMENT
HEPATITIS C : RECENT ADVANCES IN SCREENING & MANAGEMENT 6/27/2014 C Stands for Cure. Kirti Shetty, MD Associate Professor Of Medicine Director Of Hepatology National Capital Region 1 DISCLOSURES Grant
More informationKaren E. Kim, MD Professor of Medicine Dean for Faculty Affairs Director, Center for Asian Health Equity University of Chicago
Karen E. Kim, MD Professor of Medicine Dean for Faculty Affairs Director, Center for Asian Health Equity University of Chicago 1 2 billion people have been exposed to HBV 350-400 million people chronically
More informationChronic Hepatitis C: An Update on Screening, Evaluation, and Management
Chronic Hepatitis C: An Update on Screening, Evaluation, and Management Donald Gardenier, DNP, FNP-BC, FAANP, FAAN Assistant Professor and Clinical Program Director Icahn School of Medicine at Mount Sinai
More informationHepatitis C Infection: Updated Information for Front Line Workers in Primary Care Settings MAMTA K. JAIN, MD, MPH 2/14/18
Hepatitis C Infection: Updated Information for Front Line Workers in Primary Care Settings MAMTA K. JAIN, MD, MPH 2/14/18 Overview Hepatitis C Virus Prevalence Effects of Hepatitis C Prevention Diagnosis
More informationHepatocellular Carcinoma (HCC): Burden of Disease
Hepatocellular Carcinoma (HCC): Burden of Disease Blaire E Burman, MD VM Hepatology Hepatocellular Carcinoma (HCC) Primary HCCs most often arise in the setting of chronic inflammation, liver damage, and
More informationSharing the Message of Hepatitis C and Liver Cancer in Indian Country
Sharing the Message of Hepatitis C and Liver Cancer in Indian Country Jessica Leston, DrPH (c), MPH Northwest Portland Area Indian Health Board Clinical Programs Director - HIV/HCV Objectives Describe
More informationHepatitis C. David Byers, MD, FACP Senior Medical Director for Infectious Diseases and Wound Healing Services Southern Ohio Medical Center
Hepatitis C David Byers, MD, FACP Senior Medical Director for Infectious Diseases and Wound Healing Services Southern Ohio Medical Center DISCLOSURE The speaker and members of the planning committee do
More informationPa$ent w/ HCV 5/26/2016
Ini$al of a Evalua$on(s) Pa$ent w/ HCV 5/26/2016 Objec$ves To discuss the issues involved in the ini/al encounters of a pa/ent w/ Hepa//s C Learning how to provide pa/ent educa/on about hepa//s C transmission,
More informationAgenda. Hepatitis C: Evaluation & Treatment. Background. Natural History of Hepatitis C. Epidemiology 9/23/2014
Hepatitis C: Evaluation & Treatment Amanda DeVoss, MMS, PA-C WAPA Conference Fall 2014 adevoss@wisc.edu Background Epidemiology Transmission Screening Agenda Diagnosis Evaluation Treatment Background Natural
More informationThe Changing World of Hepatitis C
The Changing World of Hepatitis C Alnoor Ramji Gastroenterology & Hepatology Clinical Associate Professor Division of Gastroenterology University Of British Columbia St. Paul s Hospital Site Disclosures
More informationHepatitis C Management and Treatment
Hepatitis C Management and Treatment Kaya Süer Near East University Faculty of Medicine Infectious Diseases and Clinical Microbiology 1 Discovery of Hepatitis C Key facts Hepatitis C: the virus can cause
More informationAfter the Cure: Looking Ahead in HCV Management. Nancy Reau, MD
After the Cure: Looking Ahead in HCV Management Nancy Reau, MD Objectives 1. Discuss current recommendations in HCV screening, performance and limitations 2. Discuss linkage to care, hurdles and strategies
More informationHepatitis C in Disclosures
Hepatitis C in 2018 Sandeep Mukherjee, MD CHI Health and Creighton University Medical Center Division of Gastroenterology Grant support: Abbvie Disclosures Speaker: Abbvie, Gilead, Merck Section editor
More informationObstacles and Opportunities on Our Path Toward Eliminating Viral Hepatitis
Obstacles and Opportunities on Our Path Toward Eliminating Viral Hepatitis Jonathan Mermin, MD, MPH National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention Centers for Disease Control and
More informationViral Hepatitis The Preventive Potential of Antiviral Therapy. Thomas Berg
Viral Hepatitis The Preventive Potential of Antiviral Therapy Thomas Berg Therapeutic and preventive strategies in patients with hepatitis virus infection Treatment of acute infection Treatment of chronic
More informationHepatitis B. What's the impact on the risk? Dr Himanshu Bhatia, Asia Chief Medical Officer ALUCA, Brisbane, Sept 2013
Hepatitis B What's the impact on the risk? Dr Himanshu Bhatia, Asia Chief Medical Officer ALUCA, Brisbane, Sept 2013 Some quick facts about Hepatitis B Worldwide: 350-400 Million are chronic infections
More informationMortality from viral hepatitis in the Netherlands. S.W. Schalm & M.Toy. Dpts Gastroenterology Hepatology and Public Health Erasmus MC, Rotterdam, NL
Mortality from viral hepatitis in the Netherlands S.W. Schalm & M.Toy Dpts Gastroenterology Hepatology and Public Health Erasmus MC, Rotterdam, NL Burden of disease: chronic viral hepatitis in NL annual
More informationManagement of Hepatitis C in Primary Care BABAFEMI ONABANJO, MD & BEN ALFRED, FNP UMASS FAMILY HEALTH CENTER WORCESTER
Management of Hepatitis C in Primary Care BABAFEMI ONABANJO, MD & BEN ALFRED, FNP UMASS FAMILY HEALTH CENTER WORCESTER Objective Epidemiology Screening criteria Appropriate work up Treatment Guidelines
More informationUpdates in the Treatment of Hepatitis C
Disclosures Updates in the Treatment of Hepatitis C Arslan Kahloon M.D Assistant Professor of Medicine University of Tennessee, Chattanooga I have no conflicts of interest or financial sponsorship to disclose
More informationUpdate of hepa++s E in Hong Kong. Dr Chow Chi Wing Department of Medicine Tseung Kwan O Hospital
Update of hepa++s E in Hong Kong Dr Chow Chi Wing Department of Medicine Tseung Kwan O Hospital HEV: The History Probably causing human disease for centuries Iden+fied on EM by Dr Balayan in 1983 Viral
More informationIs Elimination of Hepatitis C Possible?
Is Elimination of Hepatitis C Possible? JORGE MERA, MD CHEROKEE NATION DISCLOSURE INFORMATION The presenter has nothing to disclose. Outline Scope of the problem Definitions Is elimination of HCV needed?
More informationSummary of Key Points. WHO Position Paper on Vaccines against Hepatitis B, July 2017
Summary of Key Points WHO Position Paper on Vaccines against Hepatitis B, July 2017 1 Background l HBV is transmitted by exposure of mucosal membranes or non-intact skin to infected blood, saliva, semen
More informationHCV Epidemiology, Screening, Natural History, and Extra-Hepatic Manifestations
HCV Epidemiology, Screening, Natural History, and Extra-Hepatic Manifestations Paul Y. Kwo, MD, FACG Professor of Medicine Director of Hepatology Stanford University Hepatitis C Virus Page 1 of 22 The
More informationThe Chronic Liver Disease Foundation (CLDF) and the International Coalition of Hepatology Education Providers (IC-HEP) present:
The Chronic Liver Disease Foundation (CLDF) and the International Coalition of Hepatology Education Providers (IC-HEP) present: Certified by: Provided by: Endorsed by: Hepatocellular Carcinoma HCC: Age
More informationNew York State HCV Provider Webinar Series
New York State HCV Provider Webinar Series Treatment of HCV/HIV Co-Infection Dost Sarpel, MD Division of Infectious Disease Viral Hepatology Milford Regional Medical Center Objectives Review the epidemiology
More informationOverview of Hepatitis C Virus: The Challenge & The Opportunity. Cody A. Chastain, MD
Overview of Hepatitis C Virus: The Challenge & The Opportunity Cody A. Chastain, MD Disclosures Research supported by Gilead Sciences Inc.: Site investigator for HIV/HCV SWITCH Registry Study Key faculty
More informationHepatitis B Epidemiology and Prevention in the Elimination Era John W. Ward, MD
Hepatitis B Epidemiology and Prevention in the Elimination Era John W. Ward, MD Director, Program for Viral Hepatitis Elimination, Task Force for Global Health Senior Scientist, National Center for HIV/AIDS,
More informationHepatitis C COLVILLE FOCUSED DIAGNOSIS, MANAGEMENT, TREATMENT
Hepatitis C COLVILLE FOCUSED DIAGNOSIS, MANAGEMENT, TREATMENT Background and affiliations BS (MIT); 3 years in international health (Mexico City and Honduras with Peace Corps); MS (Colorado State University);
More informationThe ABCs of Viral Hepatitis Diagnosis. Ila Singh, M.D., Ph.D. P & S Viral Hepatitis. Hepatitis A, B, C, D, E and G viruses
The ABCs of Viral Hepatitis Diagnosis Ila Singh, M.D., Ph.D. P & S 14-453 is132@columbia.edu Viral Hepatitis Hepatotropic viruses Hepatitis A, B, C, D, E and G viruses Generalized infection plus infection
More informationHepatitis C Virus. https://www.labcorp.com/wps/wcm/connect/labcorp+content/labcorp/education+and+re...
Page 1 of 16 Hepatitis C Virus Data reflected in this report are based solely on the collection of samples submitted to LabCorp for testing. Refer to the limitations section of this report for additional
More informationOutline. Updates in the Clinical Management of Hepatitis B and C. Who should be screened for HBV? Chronic Hepatitis B 10/7/2018
Outline Updates in the Clinical Management of Hepatitis B and C Jennifer C. Lai, MD, MBA Transplant Hepatologist Associate Professor of Medicine In Residence University of California, San Francisco Initial
More informationANTIVIRAL THERAPY FOR HCV. Alfredo Alberti
CLINICAL IMPACT OF SVR AFTER ANTIVIRAL THERAPY FOR HCV Alfredo Alberti Department of Histology,Microbiology and Medical Biotechnologies Molecular Hepatology Unit Venetian Institute of Molecular Medicine
More informationHepatitis C in Massachusetts Michael Gaucher and Shauna Onofrey MA Department of Public Health Bureau of Infectious Disease & Laboratory Sciences
Massachusetts Department of Public Health Bureau of Infectious Disease and Laboratory Sciences Hepatitis C in Massachusetts Michael Gaucher and Shauna Onofrey MA Department of Public Health Bureau of Infectious
More informationDepartment of Veterans Affairs
Department of Veterans Affairs HEPATITIS C TREATMENT : REQUEST FOR CHOICE PROGRAM FLEXIBILITY TO ADDRESS $500 MILLION SHORTFALL IN FY 2015 7/14/15 1 Veteran Hepatitis-C Treatment: Summary VA is changing
More informationChronic viral hepatitis and liver disease in Belgium Pierre Deltenre
Chronic viral hepatitis and liver disease in Belgium Pierre Deltenre Brussels, November 7, 2017 Hepatitis B and C in Belgium What we need to know 1. Who is at risk of infection? 2. What is the natural
More informationPennsylvania Academy of Family Physicians Foundation & UPMC 43rd Refresher Course in Family Medicine CME Conference March 10 13, 2016
Pennsylvania Academy of Family Physicians Foundation & UPMC 43rd Refresher Course in Family Medicine CME Conference March 10 13, 2016 Disclosures: Hep C Update N. Randy Kolb, MD Speakers has received Funding
More informationHCV elimination : lessons from Scotland
HCV elimination : lessons from Scotland Sharon Hutchinson Glasgow Caledonian University / Health Protection Scotland BHIVA Hepatology Highlights, Edinburgh, 17 th April 2018 Disclosures Honoraria from
More informationAppendix Table A Frequency of end-stage liver disease in inception cohort. Reference Exposure followup Frequency ESLD (%) Seeff-1 PTH 24 23/568 (4%) 7
Published as supplied by the author Appendix Table A Frequency of end-stage liver disease in inception cohort studies Route of Years Reference Exposure followup Frequency ESLD (%) Locasciulli PTH 1 15
More informationPlacing the United States on the Path Toward the Elimination of Hepatitis C as a Public Health Threat
Placing the United States on the Path Toward the Elimination of Hepatitis C as a Public Health Threat John W. Ward, M.D Division of Viral Hepatitis National Center for HIV/AIDS, Viral Hepatitis, STD &
More informationNegative Hepatitis C Reporting and Linkage to Care Outreach
Negative Hepatitis C Reporting and Linkage to Care Outreach NASTAD 7 th National Hepatitis Technical Assistance Meeting November 28-30, 2017 Angelica Bocour, MPH Director of Viral Hepatitis Surveillance
More informationA Practical Guide to Hepatitis C Management
A Practical Guide to Hepatitis C Management David C. Wolf, M.D., FACP, FACG, AGAF Medical Director of Liver Transplantation Westchester Medical Center Professor of Clinical Medicine New York Medical College
More informationFull Duration Management of Hepatitis C in General Hospital via IT System ---- a case from Peking University People s Hospital
Full Duration Management of Hepatitis C in General Hospital via IT System ---- a case from Peking University People s Hospital WEI Lai, Vice President, Peking University People s Hospital Oct 2nd, 2014
More informationUpdate on HCV and other infections related to injection drug use. Ann Thomas, MD, MPH Acute and Communicable Disease Prevention
Update on HCV and other infections related to injection drug use Ann Thomas, MD, MPH Acute and Communicable Disease Prevention Dec 14, 2018 Overview Update on NHANES prevalence data Trends in HCV, HIV
More informationAntiviral agents in HCV
Antiviral agents in HCV : Upcoming Therapeutic Options Su Jong Yu, M.D., Ph.D. Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine Estimated 170 Million
More informationHEPATITIS C, ACUTE CRUDE DATA. Number of Cases 5 Annual Incidence a LA County 0.05 California b 0.10 United States b 0.68 Age at Diagnosis Mean 38
2016 Annual Morbidity Report HEPATITIS C, ACUTE a Rates calculated based on less than 19 cases or events are considered unreliable b Calculated from: CDC. Notice to Readers: Final 2016 Reports of Nationally
More informationHIV/HCV Co-Infec0on Watch: 2017 Annual Monitoring Report
HIV/HCV Co-Infecon Watch: 21 Annual Monitoring Report The HIV/HCV Co-Infecon Watch is a publicaon of the Community Access Naonal Network (CANN). It is a paent-centric informaonal portal serving three primary
More informationHRSA Ini)a)ves to Address Hepa))s C and Health Dispari)es September 7, 2017
HRSA Ini)a)ves to Address Hepa))s C and Health Dispari)es September 7, 2017 Letha Healey, MD Pamela Belton Sara Woody Division of Domes)c HIV Programs Office of Training and Capacity Development (OTCD)
More informationHepatitis B. Epidemiology and Natural History and Implications for Treatment
Hepatitis B Epidemiology and Natural History and Implications for Treatment Norah Terrault, MD Professor of Medicine and Surgery Director, Viral Hepatitis Center University of California San Francisco
More information